Andrew Parkinson

10.0k total citations · 1 hit paper
120 papers, 6.4k citations indexed

About

Andrew Parkinson is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Andrew Parkinson has authored 120 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Pharmacology, 39 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Andrew Parkinson's work include Pharmacogenetics and Drug Metabolism (84 papers), Drug Transport and Resistance Mechanisms (33 papers) and Hormonal and reproductive studies (15 papers). Andrew Parkinson is often cited by papers focused on Pharmacogenetics and Drug Metabolism (84 papers), Drug Transport and Resistance Mechanisms (33 papers) and Hormonal and reproductive studies (15 papers). Andrew Parkinson collaborates with scholars based in United States, Canada and United Kingdom. Andrew Parkinson's co-authors include Stephen Safe, Ajay Madan, Edward L. LeCluyse, Michael P. Arlotto, Peter L. Bullock, David R. Dutton, Andrew J. Sonderfan, Robin E. Pearce, Brian W. Ogilvie and Faraz Kazmi and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and Advanced Drug Delivery Reviews.

In The Last Decade

Andrew Parkinson

118 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid

1987 543 citations Andrew Parkinson et al. profile →

Peers

Countries citing papers authored by Andrew Parkinson

Since Specialization

Citations

This map shows the geographic impact of Andrew Parkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Parkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Parkinson more than expected).

Fields of papers citing papers by Andrew Parkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Parkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Parkinson. The network helps show where Andrew Parkinson may publish in the future.

Co-authorship network of co-authors of Andrew Parkinson

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Parkinson. A scholar is included among the top collaborators of Andrew Parkinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Parkinson. Andrew Parkinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study 2023 ·Lara D. Veeken ·Philip Helliwell, Laura C. Coates, (unknown), (unknown), Jon Packham, (unknown), William Tillett, Neil McHugh, (unknown), (unknown), Emma Dures, (unknown), Vishnu Madhok, Catherine Smith, Eldon Spackman, Andrew Parkinson, (unknown), (unknown)	2
2	Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs 2022 ·Lara D. Veeken ·Laura Tucker, Alexander Allen, David Chandler, Coziana Ciurtin, Andrew D. Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak R. Jadon, Gareth T. Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, William Tillett, Laura C. Coates	3
3	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs 2022 ·Lara D. Veeken ·Laura Tucker, Alexander Allen, David Chandler, Coziana Ciurtin, Andrew D. Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak R. Jadon, Gareth T. Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, William Tillett, Laura C. Coates	9
4	Patients’ perspectives of telemedicine appointments for psoriatic arthritis during the COVID-19 pandemic: results of a patient-driven pilot survey 2022 ·BMC Rheumatology ·Hannah Jethwa, Melanie Brooke, Andrew Parkinson, Emma Dures, Nicola Gullick	5
5	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope 2020 ·Lara D. Veeken ·William Tillett, Alexander Allen, Laura Tucker, David Chandler, Coziana Ciurtin, (unknown), Andrew D. Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak R. Jadon, Gareth T. Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, Laura C. Coates	3
6	An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides 2018 ·Drug Metabolism and Disposition ·Faraz Kazmi, Phyllis Yerino, (unknown), Andrew Parkinson, David B. Buckley, Brian W. Ogilvie	18
7	The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments 2015 ·Drug Metabolism and Disposition ·L. Haupt, Faraz Kazmi, Brian W. Ogilvie, David B. Buckley, Brian D. Smith, Sarah Leatherman, Brandy L. Paris, (unknown), Andrew Parkinson	50
8	Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso/Oxime Metabolite Formed via a Nitrone Intermediate 2013 ·Drug Metabolism and Disposition ·(unknown), Faraz Kazmi, Andrew Parkinson, David B. Buckley	28
9	Construction of Triple-Transfected Cells [Organic Anion-Transporting Polypeptide (OATP) 1B1/Multidrug Resistance-Associated Protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for Analysis of the Sinusoidal Function of MRP3 and MRP4 2009 ·Drug Metabolism and Disposition ·Masakazu Hirouchi, Hiroyuki Kusuhara, Reiko Onuki, Brian W. Ogilvie, Andrew Parkinson, Yuichi Sugiyama	32
10	On the Mechanism of Hepatocarcinogenesis of Benzodiazepines: Evidence that Diazepam and Oxazepam are CYP2B Inducers in Rats, and both CYP2B and CYP4A Inducers in Mice 2006 ·Drug Metabolism Reviews ·Andrew Parkinson, (unknown), Alison J. Draper, Brian W. Ogilvie	15
11	Assessing Indirect Impacts of the EC Proposals for Video Regulation 2006 ·Discovery Research Portal (University of Dundee) ·Christopher T. Marsden, Jonathan Cave, Edward Nason, Andrew Parkinson, Colin Blackman, Jason Rutter	12
12	Regulation of Drug Transporter Gene Expression by Nuclear Receptors 2003 ·Drug Metabolism and Disposition ·Jeff L. Staudinger, Ajay Madan, (unknown), Andrew Parkinson	114
13	Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A69) 2003 ·Pharmacogenetics* ·Kazuma Kiyotani, Hiroshi Yamazaki, Masaki Fujieda, Shunsuke Iwano, Keiko Matsumura, Soisungwan Satarug, Pailin Ujjin, Tsutomu Shimada, F. Peter Guengerich, Andrew Parkinson, (unknown), Kazuko Nakagawa, Takashi Ishizaki, Tetsuya Kamataki	58
14	Twenty One Novel Single Nucleotide Polymorphisms (SNPs) of the CYP2A6 Gene in Japanese and Caucasians 2002 ·Drug Metabolism and Pharmacokinetics ·Kazuma Kiyotani, Masaki Fujieda, Hiroshi Yamazaki, Tsutomu Shimada, F. Peter Guengerich, Andrew Parkinson, Kazuko Nakagawa, Takashi Ishizaki, Tetsuya Kamataki	31
15	Safety of acid-suppressing drugs 1995 ·Digestive Diseases and Sciences ·Richard A. Smallwood, Roger G. Berlin, Neal Castagnoli, H.P.M. Festen, Christopher J. Hawkey, SK Lam, M. J. S. Langman, Per Lundborg, Andrew Parkinson	25
16	Rat Serum Carboxylesterase 1995 ·Journal of Biological Chemistry ·Bingfang Yan, Dongfang Yang, Peter L. Bullock, Andrew Parkinson	73
17	Role of flavin-dependent monooxygenases and cytochrome P450 enzymes in the sulfoxidation of S-methyl N,N-diethylthiolcarbamate 1993 ·Biochemical Pharmacology ·Ajay Madan, Andrew Parkinson, Morris D. Faiman	29
18	Regulation of two electrophoretically distinct proteins recognized by antibody against rat liver cytochrome P450 3A1 1992 ·Journal of Biochemical Toxicology ·Brian Gemzik, (unknown), (unknown), Andrew Parkinson	22
19	Cytochrome P450 IIIA1 (P450p) requires cytochrome b5 and phospholipid with unsaturated fatty acids 1991 ·Archives of Biochemistry and Biophysics ·(unknown), Andrew Parkinson	32
20	Purification of rat liver microsomal cytochrome P‐450b without the use of nonionic detergent 1988 ·Journal of Biochemical Toxicology ·David R. Dutton, (unknown), Andrew Parkinson	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact